ALLEN HUBERT L 4
4 · ABBOTT LABORATORIES · Filed Oct 23, 2024
Insider Transaction Report
Form 4
ALLEN HUBERT L
Executive Vice President
Transactions
- Sale
Common shares without par value
2024-10-21$116.98/sh−150,271$17,578,702→ 184,806 total - Exercise/Conversion
Common shares without par value
2024-10-21$47.00/sh+157,421$7,398,787→ 342,227 total - Sale
Common shares without par value
2024-10-21$118.81/sh−1,249$148,394→ 340,978 total - Sale
Common shares without par value
2024-10-21$118.15/sh−5,901$697,203→ 335,077 total - Exercise/Conversion
Option (right to buy)
2024-10-21−157,421→ 0 totalExercise: $47.00From: 2018-02-20Exp: 2025-02-19→ Common shares (157,421 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.68 to $118.92, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.68 to $118.59, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.68 to $117.64, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.